News
PODD
149.81
+2.25%
3.30
Insulet price target raised to $160 from $153 at Truist
TipRanks · 13h ago
Insulet Price Target Raised to $160.00/Share From $153.00 by Truist Securities
Dow Jones · 13h ago
Truist Securities Reiterates Hold on Insulet, Raises Price Target to $160
Benzinga · 14h ago
Insulet launches ‘Give Yourself the Freedom to’ campaign
TipRanks · 15h ago
Weekly Report: what happened at PODD last week (1102-1106)?
Weekly Report · 18h ago
For World Diabetes Day, Insulet Launches “Give Yourself the Freedom to” Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being
Barchart · 22h ago
Insulet Corp. Stock Sheds 6.2%, Underperforms Peers
Dow Jones · 3d ago
DexCom Inc. Stock Sheds 6.0%, Underperforms Market
Dow Jones · 3d ago
Nasdaq achieves a 1% advance; indexes see big losses for the week
Seeking Alpha · 3d ago
Midday Pulse: S&P 500 top intraday losers
Seeking Alpha · 3d ago
Insulet Is Maintained at Equal-Weight by Barclays
Dow Jones · 3d ago
Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $165
Benzinga · 3d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Viridian Therapeutics (VRDN), Insulet (PODD) and BeOne Medicines (ONC)
TipRanks · 3d ago
Insulet price target raised to $165 from $150 at Barclays
TipRanks · 3d ago
Insulet Is Maintained at Neutral by UBS
Dow Jones · 4d ago
Insulet Price Target Raised to $171.00/Share From $150.00 by UBS
Dow Jones · 4d ago
UBS Maintains Neutral on Insulet, Raises Price Target to $171
Benzinga · 4d ago
Insulet Price Target Raised to $170.00/Share From $152.00 by JP Morgan
Dow Jones · 4d ago
Insulet Is Maintained at Neutral by JP Morgan
Dow Jones · 4d ago
JP Morgan Maintains Neutral on Insulet, Raises Price Target to $170
Benzinga · 4d ago
More
Webull provides a variety of real-time PODD stock news. You can receive the latest news about Insulet Corp through multiple platforms. This information may help you make smarter investment decisions.
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.